Insulin Analog, Lispro Mixed Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Insulin Analog, Lispro Mixed (Humalog Mix 75/25 and Mix 50/50) continue to encounter availability challenges at retail pharmacies in 2026. While the national manufacturing supply has largely stabilized following 2024 disruptions, localized distribution gaps mean that some of your patients may be calling your office in distress — without insulin, or nearly out. This guide is designed to help you respond efficiently and safely.

Current Supply Situation: What Prescribers Need to Know

Eli Lilly discontinued Humalog 3 mL vials in early 2024 due to manufacturing delays and demand volatility. The 10 mL vials and KwikPens were not discontinued and have largely returned to normal production. However, the transition created distribution disruption that persists unevenly across geographic markets. The Humalog Mix formulations (75/25 and 50/50) are specialty products within Lilly's insulin portfolio and may be subject to allocation constraints during periods of high demand or distribution irregularities.

The FDA Drug Shortage database does not currently list Insulin Lispro Mixed as an active shortage. However, ASHP and clinical pharmacists have noted ongoing spot shortages at the pharmacy level. Providers should anticipate that patient-reported difficulty obtaining this medication does not indicate patient error or non-compliance.

Who Is Most Affected?

Patients most vulnerable to pharmacy-level availability gaps include:

• Patients in rural or underserved areas with limited pharmacy options
• Patients dependent on a single retail pharmacy without mail-order access
• Patients with insurance formularies that restrict pharmacy access
• Patients who previously used the discontinued 3 mL vial format

Clinically Appropriate Substitutions: What to Consider

When a patient cannot obtain Insulin Analog, Lispro Mixed, the following alternatives are clinically relevant:

NovoLog Mix 70/30 (insulin aspart protamine / insulin aspart): The closest pharmacodynamic analog substitute. Contains 70% intermediate-acting and 30% rapid-acting analog insulin. Onset is comparable (10–20 minutes). BID dosing schedule is the same. Dose adjustment may be required due to the different rapid:intermediate ratio. Available as vial and FlexPen.

Humulin 70/30 / Novolin 70/30: Traditional NPH/regular human insulin mixture. Slower onset (30–60 minutes), less precise postprandial control. Appropriate as a bridge if analog alternatives are also unavailable. Available OTC. Significant patient education required regarding timing changes.

Basal-bolus conversion: For Type 2 patients with stable glycemic control, converting to a basal-bolus regimen (e.g., insulin glargine once daily plus insulin lispro at mealtimes) may provide superior long-term flexibility. This is a good time to reassess whether a premixed formulation remains the optimal regimen for the patient's current lifestyle and glucose targets.

Same-family alternatives: If Humalog Mix 75/25 is unavailable but Humalog Mix 50/50 can be found, a dose reduction may be appropriate given the higher rapid-acting proportion — calculate carefully. Similarly, Humalog 50/50 to 75/25 switches require dose recalculation.

Dose Conversion Guidance for NovoLog Mix 70/30

When transitioning from Humalog Mix 75/25 to NovoLog Mix 70/30, many practitioners start with a 1:1 unit conversion and monitor closely, given the similar pharmacokinetic profiles. However, the slightly higher rapid-acting component in NovoLog Mix 70/30 (30% vs. 25%) may require a modest dose reduction, particularly if the patient has a history of hypoglycemia. Increase blood glucose monitoring frequency for the first 1–2 weeks after any insulin regimen change.

What to Tell Your Patients Who Can't Find Their Insulin

Reassure patients that their difficulty finding Insulin Analog, Lispro Mixed is a real access issue — not a sign that they are doing something wrong. Recommend that they:

1. Use medfinder to check nearby pharmacy inventory without calling each one individually.
2. Try mail-order pharmacies for 90-day supply.
3. Contact you when they have fewer than 7 days of supply remaining.
4. Never ration, dilute, or self-substitute insulin without medical guidance.

Savings Programs for Patients Paying Out of Pocket

For patients who cannot access their insurance pharmacy or are paying cash, these programs can significantly reduce cost:

• Lilly Insulin Value Program: $35/month cap for commercially insured or cash-pay patients (not Medicare/Medicaid). Available at insulins.lilly.com.
• Lilly Cares Foundation: Free insulin for low-income uninsured patients who qualify.
• Medicare IRA Cap: $35/month per insulin under Part D — patients with Medicare do not pay more for any covered insulin.
• GoodRx: As low as $81.36 for Humalog Mix 75/25 with coupon. Compare pharmacy prices at goodrx.com.

Resources for Your Practice

medfinder offers a dedicated provider portal where you can refer patients to check pharmacy availability near them. For a complete provider workflow guide, see: How to Help Your Patients Find Insulin Analog, Lispro Mixed in Stock: A Provider's Guide.